Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.

Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page
- Check6 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check21 days agoChange DetectedThe page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check28 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check50 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check64 days agoChange DetectedThe page has been updated to reflect a new version (v2.15.0) and the focus has shifted to solid tumors, specifically mentioning C14015. Additionally, significant details about the study's purpose and participant criteria have been removed.SummaryDifference21%
Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.